Citations

Clear

273 citation(s) found for "Simone, N De".

A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury
Cheng, Jinping , Jiang, Jingru, He, Baixuan, Lin, Wei‐Jye , Li, Yi , Li, Honghong , Huang, Xiaolong , Xie, Jiatian, Zhang, Zhan , Yang, Yuhua , Xu, Yongteng , Hu, Xia , Wu, Minyi, Zhuo, Xiaohuang , Pei, Yu , Rong, Xiaoming , Ye, Xiaojing , Saw, Phei Er , Wu, Long‐Jun , Mai, Hai‐Qiang , Tang, Yamei , Li, Honghong , Zhang, Zhan , Xu, Yongteng , Shi, Zhongshan , Ye, Xiaojing , Saw, Phei Er , Wu, Long-Jun , Simone, Charles B , Chua, Melvin L K , Tang, Yamei , Duan, Jingjing, Cai, Jinhua , Hu, Xia, Liu, Qiang , Yu, Pei, Simone, Charles B. , Chua, Melvin L.K. , Mai, Hai‐Qiang

Mayo Clinic

Science Translational Medicine | February 22, 2023 | Volume: 15 | Issue: 684 | Pages: No page available

10.1126/scitranslmed.abm6543 | PMID 36812346 Get It

Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon’s minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery–magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues–Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Sen, Parikshit , Naveen, R, Houshmand, Nazanin , Moghadam‐Kia, Siamak , Joshi, Mrudula , Saha, Sreoshy , Jagtap, Kshitij , Agarwal, Vishwesh , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chatterjee, Tulika , Day, Jessica , Chinoy, Hector , Group, COVAD Study, Kardeş, Sinan , Lini, Daniele , Screiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pande, Arun K. , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Fusaro, Enrico , Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Venerito, Vincenzo , Grignaschi, Silvia, Giollo, Alessandro, Alluno, Alessia, Ioannone, Florenzo, Loarce‐Martos, Jesus , Prieto‐González, Sergio , González, Raquel , Yoshida, Akira , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Emorinken, Airenakho , Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Sáenz, Ricardo A., Escalante, Miguel , Morales, Roberto, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Gupta, Latika, Ravichandran, Naveen , Giollo, Alessandro , Grignaschi, Silvia , Gupta, Latika , Naveen, R , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Day, Jessica , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Agarwal, Vishwesh , Tan, Ai Lyn , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , Yoshida, Akira , De Angelis, Rossella , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Makol, Ashima , Chen, Yi‐Ming , Distler, Oliver , Group, COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Fonseca, João Eurico , Zimba, Olena , Ugarte‐Gil, Manuel F. , Salinas, Rodrigo Nicolás Garcia , Saenz, Ricardo, Aggarwal, Rohit

Mayo Clinic

Rheumatology | February 3, 2023 | Volume: 62 | Issue: 10 | Pages: 3291-3301

10.1093/rheumatology/kead057 | PMID 36734536 Get It

Abstract Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs – OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs – OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7–10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8–0.97)]. Conclusion Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
Capdevila, Jaume , Herrmann, Ken, Leyden, Simone , Mailman, Josh , Reidy‐Lagunes, Diane , Erdö, Máté, Rotger, Amanda, Thevenet, Thomas, Hálfdánarson, Þorvarður R. , Halperin, Daniel M. , Kong, Grace , Srirajaskanthan, Rajaventhan

Mayo Clinic

Journal of Clinical Oncology | February 2, 2023 | Volume: 41 | Issue: 4_suppl | Pages: TPS660-TPS660

10.1200/jco.2023.41.4_suppl.tps660 Get It

TPS660 Background: Deeper comprehension of gastroenteropancreatic neuroendocrine tumor (GEP-NET) characteristics has led to development of therapeutic interventions such as targeted radionuclide therapies (TRT). In the prospective, randomized, controlled, open-label, multi-center, Phase III COMPOSE trial, the radiolabeled somatostatin analogue 177Lu-edotreotide will be compared to approved standard of care with everolimus, CAPTEM or FOLFOX in patients with well-differentiated aggressive grade 2 and 3 (Ki-67 index 15−55%), somatostatin receptor positive GEP-NETS. While TRT is advantageous, a key unmet need is to identify additional markers intended to guide patient selection for TRT. This is highly relevant as TRT is a therapy of growing interest likely to be broadly available for patients with variable phenotypes. Profiling analysis as part of COMPOSE plans to analyze the genetic signature of GEP-NETS through full exome sequencing and gene expression analysis of tumor histology and longitudinal blood samples. This analysis may guide detection of pathogenic mutations in NET patients, to potentially inform treatment and surveillance strategies. Methods: Whole exome analysis of tumor-suppressor- and proto-oncogenes included in several pan-cancer panels, upstream and downstream regulators, and novel candidate genes, will be studied. Following patient consent, historical tumor biopsy and blood samples will undergo genetic analysis. Genetic profiling analysis inclusion will not impact trial involvement or disease management. DNA will be assessed to determine the impact of different types of mutations; mRNA will be assessed to confirm and quantify these assumptions and compare gene expression at different treatment phases. Samples will be analyzed in a central pathology laboratory. The aim of this analysis is to develop software that would integrate genetic data with structural and functional imaging, histopathology and phenotype information for implementation into clinical practice. Clinical trial information: NCT04919226 .
Differential response to Donepezil in MRI subtypes of mild cognitive impairment
Diaz‐Galvan, Patricia , Lorenzon, Giulia , Mårtensson, Gustav , Cavedo, Enrica , Dubois, Bruno , Westman, Eric , Westman, Eric , Diaz-Galvan, Patricia , Mohanty, Rosaleena , Lista, Simone , Vergallo, Andrea , Kantarci, Kejal , Hampel, Harald , Grothe, Michel J. , Ferreira, Daniel

Mayo Clinic

No container title available | January 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2485451/v1 Get It

Abstract Background Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to Donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes. Methods From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6-12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical-AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We compared two subtyping approaches: the conventional categorical approach and an approach based on continuous dimensions. Results Donepezil treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response. Conclusions Our data suggest that individuals with MCI, with hippocampal sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment. Trial registration: Clinical Trial.gov Number: NCT00403520, Submission Date: November 21, 2006.
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome
Berardi, Giammauro , Ratti, Francesca , Nebbia, Martina , D'Souza, D.M. , Pascual, Franco , Tohme, Samer , D‘Amico, F. , Alessandris, Remo , Simonelli, Ilaria , Basso, Céleste Del , Moro, Amika , Serenari, Matteo , Rotellar, Fernando , Famularo, Simone , Hoffman, Daniel , Onkendi, Edwin, Essaji, Y. , López‐Ben, Santiago , Caula, Cèlia , Rompianesi, Gianluca , Chopra, Asmita , Hilal, Mohammad Abu , Corvera, Carlos U. , Helton, Scott , Troisi, Roberto , Simo, Kerri A. , Conrad, Claudius , Cescon, Matteo , Kwon, Choon Hyuck David , Cherqui, Daniel , Ferrone, Cristina R. , Mazzaferro, Vincenzo , Aldrighetti, Luca , Sposito, Carlo , D'Amico, Francesco E , Alessandris, Remo , Simonelli, Ilaria , Del Basso, Celeste , Fiorentini, Guido , Serenari, Matteo , Rotellar, Fernando , Ivanics, Tommy , Hoffman, Daniel , Lopez Ben, Santiago , Chopra, Asmita , Torzilli, Guido , Cleary, Sean, Ettorre, Giuseppe M , Serrano, Pablo E , Aldrighetti, Luca , Mazzaferro, Vincenzo , Ratti, Francesca , Sposito, Carlo , Dogeas, Epameinondas , Russolillo, Nadia , Fiorentini, Guido , Zimmitti, Giuseppe , Ivanics, Tommy , Sapisochín, Gonzalo , Alseidi, Adnan A. , Cleary, Sean P. , Ferrero, Alessandro , Cillo, Umberto , Geller, David A. , Kingham, T. Peter

Mayo Clinic

Hepatology | January 16, 2023 | Volume: 77 | Issue: 5 | Pages: 1527-1539

10.1097/hep.0000000000000027 | PMID 36646670 Get It

Background: Metabolic syndrome (MS) is rapidly growing as risk factor for HCC. Liver resection for HCC in patients with MS is associated with increased postoperative risks. There are no data on factors associated with postoperative complications. Aims: The aim was to identify risk factors and develop and validate a model for postoperative major morbidity after liver resection for HCC in patients with MS, using a large multicentric Western cohort. Materials and Methods: The univariable logistic regression analysis was applied to select predictive factors for 90 days major morbidity. The model was built on the multivariable regression and presented as a nomogram. Performance was evaluated by internal validation through the bootstrap method. The predictive discrimination was assessed through the concordance index. Results: A total of 1087 patients were gathered from 24 centers between 2001 and 2021. Four hundred and eighty-four patients (45.2%) were obese. Most liver resections were performed using an open approach (59.1%), and 743 (68.3%) underwent minor hepatectomies. Three hundred and seventy-six patients (34.6%) developed postoperative complications, with 13.8% major morbidity and 2.9% mortality rates. Seven hundred and thirteen patients had complete data and were included in the prediction model. The model identified obesity, diabetes, ischemic heart disease, portal hypertension, open approach, major hepatectomy, and changes in the nontumoral parenchyma as risk factors for major morbidity. The model demonstrated an AUC of 72.8% (95% CI: 67.2%–78.2%) (https://childb.shinyapps.io/NomogramMajorMorbidity90days/). Conclusions: Patients undergoing liver resection for HCC and MS are at high risk of postoperative major complications and death. Careful patient selection, considering baseline characteristics, liver function, and type of surgery, is key to achieving optimal outcomes.
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov, Agnete Overgaard , Mackie, Sarah , Hauge, Ellen‐Margrethe , Gutiérrez, Carlos Enrique Toro , Hansen, Ib Tønder , Hemmig, Andrea Katharina , Maas, Aatke van der , Gheita, Tamer A. , Nielsen, Berit Dalsgaard , Douglas, Karen, Matteson, Eric L. , Matza, Mark , Ocampo, Vanessa , Grainger, Rebecca , Bran, Andrea, Appenzeller, Simone , Goecke, Annelise, Colmán, Nelly , Keen, Helen , Kuwana, Masataka , Gupta, Latika, Salim, Babur , Harifi, Ghita , Erraoui, M. , Ziadé, Nelly , Al-Ani, Nizar Abdulateef, Ajibade, Adeola , Frølund, Line L. , Yates, Max , Pimentel-Quiroz, Víctor R. , Lyrio, André Marun , Sandovici, Maria , Geest, Kornelis S. M. van der , Brouwer, Elisabeth , Dejaco, Christian , Keller, Kresten Krarup , Gupta, Latika , Mackie, Sarah Louise , Gheita, Tamer , Conway, Richard , Monti, Sara , Sattui, Sebastian E , Grainger, Rebecca , Keen, Helen , Kuwana, Masataka , Gupta, Latika , Ziade, Nelly , Knitza, Johannes , Pimentel-Quiroz, Victor R , Van der Geest, Kornelis S M , Dejaco, Christian , Keller, Kresten Krarup , Yates, Max , Conway, Richard , Rezuş, Elena , Dasgupta, Bhaskar , Monti, Sara , Sattui, Sebastian E. , Gromova, Margarita Aleksandrovna , Helliwell, Toby

Mayo Clinic

Rheumatology | January 12, 2023 | Volume: 62 | Issue: 8 | Pages: 2797-2805

10.1093/rheumatology/keac713 | PMID 36637182 Get It

Abstract Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
Posttransplant cyclophosphamide as a platform for immunotherapy after allogeneic stem cell transplantation for multiple myeloma
Kuns, Rachel D. , Ensbey, Kathleen S., Samson, Luke, Chesi, Marta, Vučković, Slavica , Minnie, Simone A. , Chesi, Marta , Gartlan, Kate H. , Smyth, Mark J. , Hill, Geoffrey R.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 87.30-87.30

10.4049/jimmunol.204.supp.87.30 Get It

Abstract Allogeneic stem cell transplantation (alloSCT) is a highly effective, curative therapy for leukemia yet does not provide a survival benefit above autologous SCT in patients with multiple myeloma (MM). To explore this, we developed preclinical models of SCT using C57Bl/6 recipient mice and either C57Bl/6 (ASCT) or C3H.SW (alloSCT) donor grafts. Importantly, these models recapitulated the clinical setting whereby alloSCT provided superior outcomes, compared to ASCT, in recipients bearing MLL-AF9-driven acute myeloid leukemia (AML) but not in those bearing Vk*MYC-MM. Interestingly, we found that MM-specific, T cell-mediated immunity was generated after ASCT, which failed due to MM-induced T cell exhaustion. MM relapse after ASCT could be prevented by TIGIT or PD-1 targeted immune checkpoint inhibition or via depletion of suppressive CSF1-R+ myeloid cells. Conversely, after alloSCT, T cell exhaustion was driven principally by alloantigen and CD8 T cells expressed high levels of PD-1, TIGIT and TIM-3. Furthermore, Vk*MYC myeloma exploited this alloantigen-driven T cell exhaustion via expression of high levels of PD-L1 and CD155 (the cognate ligands for PD-1 and TIGIT), which were expressed minimally on MLL-AF9 AML. To exploit alloSCT in MM, we used post-transplant cyclophosphamide (PT-Cy) to delete high affinity alloreactive T cells that generate the exhausted donor T cell pool. Subsequent administration of CD137 agonists enhanced T cell activation and cytolytic activity within bone marrow, without exacerbating GVHD. Thus, PT-Cy provides a platform for optimizing immunotherapy after alloSCT.
Syngeneic stem cell transplantation generates antigen-specific T cells that maintain myeloma-immune equilibrium
Vučković, Slavica , Watkins, Thomas S., Kuns, Rachel D. , Chesi, Marta , Minnie, Simone A. , Smith, David S. , Gartlan, Kate H. , Guillerey, Camille , Markey, Kate A. , Miles, John J. , Smyth, Mark J. , Hill, Geoffrey R.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 55.19-55.19

10.4049/jimmunol.200.supp.55.19 Get It

Abstract Multiple myeloma (MM) is a largely incurable hematological malignancy characterized by clonal expansion of plasma cells in bone marrow (BM). Autologous stem cell transplantation (ASCT) remains a standard treatment for MM, allows intensive cytoreduction and induces inflammation in the context of lymphodepletion. We hypothesized that SCT may overcome myeloma-induced immune defects to restore immune-equilibrium. To address this, we developed a model of ASCT for MM using Vk*MYC myeloma. Surprisingly, we demonstrate the induction of T cell-dependent MM control after SCT as recipients of syngeneic BM grafts containing T cells had prolonged survival and reduced tumor burden compared to BM alone. This anti-myeloma activity was independent of γδ T, natural killer (NK) and NK T cells and was dependent on CD4+and CD8+ T cells. MM-primed T cells, harvested from SCT recipients with controlled MM, protected against relapse in secondary recipients and were Vk*MYC clone-specific. Recipients of MM-primed T cells had increased central memory CD8+ T cells and transfer of MM-primed CD8+ T cells was sufficient to prevent relapse. Furthermore, TCR sequencing of CD8+ T cells from mice with controlled MM revealed a higher clonotype overlap relative to MM-free SCT recipients, consistent with MM-specific T cells. Donor IFNγ secretion and signaling was critical to protective immunity and CD8+ T cells from mice with relapsed MM had impaired IFNγ production compared to those with controlled disease. Importantly, IFNγ production was profoundly augmented by CD137 agonist treatment such that majority of mice controlled disease. These data provide new insights into the mechanisms of action of SCT in myeloma and suggest the use of CD137 agonists to prevent relapse.
Paging the Clinical Informatics Community: Respond STAT to Dobbs v. Jackson's Women's Health Organization
Ravi, Akshay , Weia, Benjamin , Aarts, Jos , Ahmad, Hasan B., Araj, Ellen, Bauml, Julie A., Boyd, Andrew D. , Brecht-Doscher, Aimee, Butler‐Henderson, Kerryn , Butte, Atul J. , Cardilo, Anthony B., Chilukuri, Nymisha , Cho, Mildred K. , Cohen, Jenny K., Craven, Catherine K. , Crusco, Salvatore, Dadabhoy, Farah Z. , Dash, Dev , DeBolt, Claire , Fayanju, Oluseyi A, Fochtmann, Laura J. , Graham, Justin V., Hanna, John , Hofford, Mackenzie , Hron, Jonathan D. , Huang, Sean S, Jackson, Brian R. , Kaplan, Bonnie , Kelly, William R. , Ko, Kyungmin, Kurapati, Nikhil , Labbad, Gabriel , Lee, Julie , Leitner, Stefano, Liao, Zachary C , Melnick, Edward R. , Muniyappa, Anoop , Murray, Sara G. , Nichols-Johnson, Victoria, Novak, Laurie L. , Ogan, William Scott , Ozeran, Larry, Pageler, Natalie M. , Pandita, Deepti , Perumbeti, Ajay, Petersen, Carolyn , Pierce, Logan , Puttagunta, Raghuveer, Ramaswamy, Priya , Rogers, Kendall, Ryan, Angela M., Sarabu, Chethan , Shaw, Kate A. , Spector, Jacob D. , Starren, Justin , Stoffel, Michelle , Swanson, Karl , Tomes, Adrian, Unertl, Kim M. , Weon, Jenny L. , Wiley, Kevin , Winkelstein, Peter , Wong, Jenson, Xie, James , Yarahuan, Julia , Yung, Nathan , Zera, Chloe , Sadasivaiah, Shobha , Boyd, Andrew D , Melnick, Edward R , Petersen, Carolyn , Arvisais‐Anhalt, Simone , Benham‐Hutchins, Marge , Brecht-Doscher, Aimee, Elkin, Peter L. , Hersh, William , Kelly, William, Koppel, Ross , Lehmann, Christoph U. , Medford, Richard J , Neinstein, Aaron Barak , Rosenbloom, S. Trent , Ryan, Angela, Saleh, Sameh Nagui , Schreiber, Richard , Sim, Ida , Sirintrapun, Sahussapont Joseph , Solomonides, Anthony , Subbian, Vignesh , Trang, Karen , Whooley, Mary A. , Williamson, Drew F. K. , Ratanawongsa, Neda

Mayo Clinic

Applied Clinical Informatics | December 19, 2022 | Volume: 14 | Issue: 01 | Pages: 164-171

10.1055/a-2000-7590 | PMID 36535703 Get It

137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
Longhi, Simone , Fontana, Marianna , Gustafsson, Finn , Simões, Marcos, Grogan, Martha , Gottlieb, Robert , Kubánek, Miloš , Yu, Wen-chuhg, Sekijima, Yoshiki , White, Matthew T. , Yureneva, Elena, Jay, Patrick Y. , Vest, John, Gillmore, Julian D , Gottlieb, Robert L , Gustafsson, Finn , Maurer, Matthew J. , Fontana, Marianna , Berk, John L. , Simões, Marcos, Fernandes, Fábio Danziato , Poulsen, Steen Hvitfeldt , Damy, Thibaud , Diemberger, Igor , Tahara, Nobuhiro , Tang, W.H. Wilson , Obici, Laura , González-Duarte, Alejandra , Vest, John, Gillmore, Julian D.

Mayo Clinic

European Heart Journal Supplements | December 15, 2022 | Volume: 24 | Issue: Supplement_K | Pages: No page available

10.1093/eurheartjsupp/suac121.630 Get It

Abstract Background Transthyretin-mediated (ATTR) amyloidosis is a rapidly progressive, debilitating, and fatal disease caused by misfolded TTR accumulating in multiple organs and tissues. Patients with hereditary (hATTR) amyloidosis (also known as ATTRv amyloidosis) or wild-type (wtATTR) amyloidosis with cardiomyopathy exhibit decreased survival. Patisiran, an IV RNAi therapeutic that inhibits synthesis of wt and variant TTR, was approved for the treatment of hATTR amyloidosis with polyneuropathy. Exploratory analyses of a predefined cardiac subpopulation in the APOLLO study demonstrated the potential for patisiran to improve the manifestations of cardiomyopathy in patients with hATTR amyloidosis with polyneuropathy. Objective To investigate the safety and efficacy of patisiran in patients with ATTR amyloidosis with cardiomyopathy in the ongoing APOLLO-B study (NCT03997383). Material & Methods Patients were 18–85 years of age with evidence of cardiac amyloidosis by echocardiography (end-diastolic interventricular wall thickness >12 mm), and either ATTR amyloid deposition on tissue biopsy or fulfilling nonbiopsy diagnostic criteria for ATTR amyloidosis with cardiomyopathy. Patients had a medical history of heart failure (HF) due to ATTR amyloidosis with at least 1 prior hospitalization for HF, or current clinical evidence of HF. Patients were randomized (1:1) to receive patisiran IV 0.3 mg/kg or placebo Q3W for 12 months. After the double-blind, placebo-controlled period, all patients may receive patisiran in an open-label extension period for up to 36 months. The primary endpoint was change from baseline in 6-MWT at Month 12 with patisiran treatment, compared with placebo. Secondary endpoints evaluated the effect of patisiran vs placebo at Month 12 on QOL (KCCQ-OS score) as well as two sets of composite endpoints: 1) All-cause mortality, frequency of CV events (CV hospitalizations and urgent HF visits) and change from baseline in 6-MWT; and 2) All-cause mortality and frequency of all-cause hospitalizations and urgent HF visits. The pharmacodynamic effect of patisiran on serum TTR level (change from baseline through Month 12) was also assessed. Results & Discussion Enrollment completed (359 patients) in May 2021. About 80% of patients have wtATTR amyloidosis. Primary and secondary endpoint data will be presented, including change in 6-MWT and KCCQ-OS score at Month 12, in addition to safety data. Summary & Conclusion The primary results of the APOLLO-B study will inform the potential of patisiran as a treatment for the cardiomyopathy of ATTR amyloidosis. APOLLO-B will continue to investigate the efficacy and safety of patisiran on ATTR amyloidosis in an open-label extension period.